In the last decade, the rapid advance of a variety of innovative technologies, such as immune repertoire sequencing, multi-omics, systems biology and networks, and deep learning have led to our understanding of cancer immunity increased from a holistic and symbiotic perspective. Meantime, innovative therapeutic strategies, such as cancer immunotherapy, have shown impressive clinical benefits in some types of cancers, such as gynecologic and urologic cancers. However, there are still many challenges to systemically evaluate cancer's immune signatures and avoid drug resistance and the side effect of immunotherapy. Therefore, new insights to the study of immune profiling, predictive/prognostic biomarkers, and drug resistance in molecular targeted therapy and immunotherapy are important and meaningful for cancer study and treatment. By high-throughput sequencing of B- or T-cell receptors, the immune “repertoires” across time or in different tissues could be traced in cancer progression; In addition, the integration of multi-omics data across the different function levels, including immune repertoires, checkpoint biomarkers, and metabolomes might be a breakthrough and provide unparalleled information to understand the biology of cancer and novel therapeutic strategies to treat gynecologic and urologic cancers, etc.
In this Research Topic, we would like to address the ongoing challenges and new frontiers related to immunity evaluation, especially the immune repertoires profiling, and modulation, with emphasis on immunotherapy, in the diagnosis and treatment of gynecologic and urologic cancer.
We welcome the submission of Original Research Articles, Reviews, Mini-Reviews, Methods, and Perspectives covering, but not limited to, the following topics:
• T cell receptor (TCR) or B cell receptor (BCR) profiling in clinical or animal models of gynecologic and urologic cancers, such as bladder cancer, cervical cancer, and ovarian cancer
• Innovative experimental models to study immunotherapy in gynecologic and urologic cancers, such as tumor organoid cocultured with immune components
• Features and receptor clonal dynamics of T cell in gynecologic and urologic cancers under innovative immunotherapy, such as immune checkpoint inhibitors
• Discovery of immune signature as novel predictive/prognostic biomarkers for gynecologic and urologic cancers
• Exploration and development of therapeutic drugs for cancer immunotherapy, such as proteins, PROTAC, peptides, small molecules, etc. to treat gynecologic and urologic cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In the last decade, the rapid advance of a variety of innovative technologies, such as immune repertoire sequencing, multi-omics, systems biology and networks, and deep learning have led to our understanding of cancer immunity increased from a holistic and symbiotic perspective. Meantime, innovative therapeutic strategies, such as cancer immunotherapy, have shown impressive clinical benefits in some types of cancers, such as gynecologic and urologic cancers. However, there are still many challenges to systemically evaluate cancer's immune signatures and avoid drug resistance and the side effect of immunotherapy. Therefore, new insights to the study of immune profiling, predictive/prognostic biomarkers, and drug resistance in molecular targeted therapy and immunotherapy are important and meaningful for cancer study and treatment. By high-throughput sequencing of B- or T-cell receptors, the immune “repertoires” across time or in different tissues could be traced in cancer progression; In addition, the integration of multi-omics data across the different function levels, including immune repertoires, checkpoint biomarkers, and metabolomes might be a breakthrough and provide unparalleled information to understand the biology of cancer and novel therapeutic strategies to treat gynecologic and urologic cancers, etc.
In this Research Topic, we would like to address the ongoing challenges and new frontiers related to immunity evaluation, especially the immune repertoires profiling, and modulation, with emphasis on immunotherapy, in the diagnosis and treatment of gynecologic and urologic cancer.
We welcome the submission of Original Research Articles, Reviews, Mini-Reviews, Methods, and Perspectives covering, but not limited to, the following topics:
• T cell receptor (TCR) or B cell receptor (BCR) profiling in clinical or animal models of gynecologic and urologic cancers, such as bladder cancer, cervical cancer, and ovarian cancer
• Innovative experimental models to study immunotherapy in gynecologic and urologic cancers, such as tumor organoid cocultured with immune components
• Features and receptor clonal dynamics of T cell in gynecologic and urologic cancers under innovative immunotherapy, such as immune checkpoint inhibitors
• Discovery of immune signature as novel predictive/prognostic biomarkers for gynecologic and urologic cancers
• Exploration and development of therapeutic drugs for cancer immunotherapy, such as proteins, PROTAC, peptides, small molecules, etc. to treat gynecologic and urologic cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
